Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses
NCT02012309Unknown
- Sponsor
- University of Colorado Denver
- Start
- Aug 2014
- Primary completion
- Jun 2021
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Open-label trial of pneumococcal 13-valent conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection (2 arms), sponsored by University of Colorado Denver. Primary endpoints: B and T cell subsets at 16 weeks, Total Immunoglobulin G, M and A at 16 weeks and 2 more. Status: unknown.
02
Drugs
pneumococcal 13-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02012309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02012309.